Crisugabalin is named as a drug or biological intervention in 4 clinical trials in our China trial register, 3 of which are recruiting. Lead sponsors include Tang-Du Hospital (1), Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) and Anhui Medical University (1). Registered phases: Phase 2, Phase 4 and Not applicable. Conditions studied include Neuropathic Pain; Neuromyelitis Optica Spectrum Disorders (NMOSD); Generalized Anxiety Disorder.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06766916 | Crisugabalin for Radiotherapy-Related Neuropathic Pain (ClinicalTrials.gov ↗) Neuropathic Pain |
Phase 2 | Recruiting |
| NCT07330648 | Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder (ClinicalTrials.gov ↗) Generalized Anxiety Disorder |
Phase 2 | Recruiting |
| NCT07196657 | The Efficacy and Safety of Pregabalin and Crisugabalin in Patients With Fibromyalgia (ClinicalTrials.gov ↗) Fibromyalgia, Pregabalin, Pain |
Not applicable | Recruiting |
| NCT07699770 | Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial Neuromyelitis Optica Spectrum Disorders (NMOSD), Neuropathic Pain |
Phase 4 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Neuropathic Pain | 2 |
| Neuromyelitis Optica Spectrum Disorders (NMOSD) | 1 |
| Generalized Anxiety Disorder | 1 |
| Fibromyalgia | 1 |
| Pregabalin | 1 |
| Pain | 1 |
| Lead sponsor | Trials |
|---|---|
| Tang-Du Hospital | 1 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 1 |
| Anhui Medical University | 1 |
| Beijing Tiantan Hospital | 1 |
| Register | Crisugabalin trials |
|---|---|
| Clinical trials in China | 4 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Crisugabalin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Crisugabalin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.